Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 2/2015

01-02-2015

A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases

Auteurs: Katy Gallop, Cicely Kerr, Stacey Simmons, Bryan McIver, Ezra E. W. Cohen

Gepubliceerd in: Quality of Life Research | Uitgave 2/2015

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

This study explored the impact of differentiated thyroid cancer (DTC) on health-related quality of life (HRQL) at different treatment phases and evaluated the validity of published DTC utilities and generic health utility measures (EQ-5D and SF-6D) for economic evaluation of treatments for radio-iodine (RAI) refractory DTC.

Methods

Focus groups and interviews were conducted with DTC patients grouped by treatment phase. Qualitative thematic analysis was conducted on interview/focus group transcripts. A thematic coding framework was developed to compare experiences between treatment phases and inform development of a conceptual model. Model concepts were mapped to EQ-5D and SF-6D domains/items.

Results

Eight focus groups and 11 individual interviews were conducted with 52 DTC patients. Fifty symptoms and HRQL concepts were identified. The impact of DTC and DTC treatment on emotional and cognitive functioning was reported across the treatment phases. The impact on daily activities, mobility, and energy levels was greatest for patients with recurring/persistent or RAI-refractory DTC. Of the 50 concepts, 25 and 27 mapped directly onto domains/items in the EQ-5D and SF-6D, respectively. The SF-6D covered a broader range of DTC impact on emotional/physical problems and daily/social activities than did the EQ-5D.

Conclusions

The conceptual model summarizes the wide-ranging impact of DTC and its treatment on patients’ HRQL, particularly for those with recurring/persistent or RAI-refractory DTC. Findings suggest that published DTC utilities lack validity for RAI-refractory DTC and that the SF-6D may be more sensitive to HRQL impact of DTC than the EQ-5D.
vorige artikel The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers
volgende artikel A methodological review of the Short Form Health Survey 36 (SF-36) and its derivatives among breast cancer survivors
Literatuur
1.
Fernandes, J. K., Day, T. A., Richardson, M. S., & Anand, K. S. (2005). Overview of the management of differentiated thyroid cancer. Current Treatments Options in Oncology, 6, 47–57.CrossRef
2.
Howlader, N., Noone, A. M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S. F., et al. (2012). SEER cancer statistics review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2009_​pops09/​, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
3.
American Cancer Society. (2013). Cancer facts & figures 2013. Atlanta: American Cancer Society.
4.
Capdevilla, J., Argiles, G., Rodriguez-Frexinos, A., Nunez, I., & Tabernero, J. (2010). New approaches in the management of radioiodine-refractory thyroid cancer: The molecular targeted therapy era. Discovery Medicine, 9, 153–162.
5.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics, 2009. CA Cancer Journal for Clinicians, 59, 225–249.CrossRef
6.
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., et al. (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167–1214.PubMedCrossRef
7.
Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., et al. (2006). Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. Thyroid, 91, 2892–2899.
8.
Stajduhar, K. I., Neithercut, J., Chu, A., et al. (2000). Thyroid cancer: Patients’ experiences of receiving iodine-131 therapy. Oncology Nursing Forum, 27(8), 1213–1218.PubMed
9.
Sawka, A. M., Goldstein, D. P., Brierley, J. D., Tsang, R. W., Rotstein, L., Ezzat, S., et al. (2009). The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: A qualitative study. PLoS ONE, 4(1), 1–8.CrossRef
10.
Schultz, P., Stava, C., & Vassilopoulou-Sellin, R. (2003). Health profiles and quality of life of 518 survivors of thyroid cancer. Head and Neck, 25(5), 349–356.PubMedCrossRef
11.
Huang, S., Lee, C., Chien, L., et al. (2004). Postoperative quality of life among patients with thyroid cancer. Journal of Advanced Nursing, 47(5), 492–499.PubMedCrossRef
12.
Crevenna, R., Zettinig, G., Keilani, M., et al. (2003). Quality of life in patients with non-metastic differentiated thyroid cancer under thyroxine supplementation therapy. Supportive Care in Cancer, 11, 597–603.PubMedCrossRef
13.
Hoftijzer, H., Heemstra, K., Corssmit, E., et al. (2008). Quality of life in cured patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 93(1), 200–203.PubMedCrossRef
14.
Botella-Carretero, J., Gala, J., Caballero, C., et al. (2003). Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer, 10, 601–610.PubMedCrossRef
15.
Lee, J., Kim, S., Tan, A., et al. (2010). Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea. Health and Quality of Life Outcomes, 8, 101.PubMedCentralPubMedCrossRef
16.
Tan, L., Nan, L., Thumboo, J., et al. (2007). Rhinological and Otological Society, Inc., health-related quality of life in thyroid cancer survivors. The Laryngoscope, 117, 507–510.PubMedCrossRef
17.
Almeida, J., Vartanian, J., Kowalski, L., et al. (2009). Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Archives of Otolaryngology-Head & Neck Surgery, 135(4), 342–346.CrossRef
18.
Mernagh, P., Campbell, S., Dietlein, M., et al. (2006). Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective. European Journal of Endocrinology, 155, 405–414.PubMedCrossRef
19.
Wang, T., Cheung, K., Mehta, P., et al. (2010). Recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. Journal of Clinical Endocrinology and Metabolism, 95(4), 1672–1680.PubMedCrossRef
20.
Mernagh, P., Suebwongpat, A., Silverberg, J., et al. (2010). Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: The Canadian perspective. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 13(2), 180–187.CrossRef
21.
Esnaola, N., Cantor, S., Huang, S., et al. (2001). Optimal treatment strategy in patients. Postoperative quality of life among patients with papillary thyroid cancer: A decision analysis. Journal of Advanced Nursing, 47(5), 492–499.
22.
Kebebew, E., Duh, Q., & Clark, O. (2000). Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model. World Journal of Surgery, 24, 1295–1302.PubMedCrossRef
23.
Brose, M. S., Nutting, C. M., Jarzab, B., et al. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. doi:10.​1016/​S0140-6736(14)60421-9.
24.
Schlumberger, M., Jarzab, B., Elisaei, R., et al. (2013). Phase III randomized, double-blinded, placebo-controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)—Exploratory analysis of patient-reported outcomes. Thyroid, 23(Suppl. 1), A-49. Oral 100.
25.
Pacini, F., Ladenson, P. W., Schlumberger, M., et al. (2006). Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. Journal of Clinical Endocrinology and Metabolism, 91(3), 926–932.PubMedCrossRef
26.
27.
MAXQDA, software for qualitative data analysis, 1989–2013, VERBI Software Consult—Sozialforschung GmbH, Berlin, Germany.
28.
The EuroQol Group. (1990). Euroqol—A new facility for the measurement of health-related quality of life. Health Policy, 16, 199–208.CrossRef
29.
Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21, 271–292.PubMedCrossRef
30.
Ware, J. E., & Gandek, G. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology, 51(11), 903–912.PubMedCrossRef
Metagegevens
Titel
A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases
Auteurs
Katy Gallop
Cicely Kerr
Stacey Simmons
Bryan McIver
Ezra E. W. Cohen
Publicatiedatum
01-02-2015
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 2/2015
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-014-0776-7

Andere artikelen Uitgave 2/2015

Quality of Life Research 2/2015 Naar de uitgave

OriginalPaper

Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients

Review

A methodological review of the Short Form Health Survey 36 (SF-36) and its derivatives among breast cancer survivors

OriginalPaper

Comparison of pre- and post-operative health-related quality of life and length of stay after primary total hip replacement in matched English and German patient cohorts

OriginalPaper

Lymphedema Quality of Life Inventory (LyQLI)-Development and investigation of validity and reliability

Brief Communication

Pooling of cross-cultural PRO data in multinational clinical trials: How much can poor measurement affect statistical power?

Brief Communication

Quality of life measures in Italian neurosurgical patients: validity of the EUROHIS-QOL 8-item index